Pharmaceutical Sector

Eli Lilly Cancer Drug fails during clinical trial

Eli Lilly and Co has reported failure of its experimental lung cancer drug for late-stage trial.

Novartis’ experimental cancer treatment wins endorsement of FDA advisers

The U.S. Food & Drug Administration (FDA) on Wednesday endorsed a first-of-its-kind cancer treatment that makes use of patients’ revved-up immune cells to fight back the deadly disease.

FDA approves new epinephrine injector from Adamis Pharmaceuticals

The U.S. Food & Drug Administration (FDA) has finally approved a new epinephrine injector for anaphylaxis, increasing competition for the controversially expensive injector EpiPen.

New Heart Failure Drug Marketing Costs to Alleviate Novartis’ 2016 Profit

Novartis revealed on Tuesday that the company is boosting its expenditure on marketing a new heart failure drug called Entresto subsequent to disappointing initial sales of the medicine. This increase in expenditure might have a dampening impact on the profit of Novartis in 2016.